Ranbaxy Diflucan Generic Delayed Until July, Court Affirms
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy's ANDAs for Diflucan may not be approved until Pfizer's pediatric exclusivity expires in July, a federal appeals court ruled